In recently released study results of the phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate across all trial subgroups. Read More ›

Lung cancer incidence rates have declined due to a decrease in risk factors and improved screening and treatment. Read More ›

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment. Read More ›

Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations. Read More ›

Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy. Read More ›

Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article. Read More ›

A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC. Read More ›

A retrospective analysis demonstrated a 10-point difference in receipt of NGS testing between white and black patients with NSCLC. Read More ›

Lung cancer remains the leading cause of cancer death worldwide, but the treatment landscape is rapidly evolving. In the past 10 years alone, the number of drugs approved by the FDA for non–small-cell lung cancer (NSCLC) has exceeded the previous 10 decades combined. Read More ›

Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations. Read More ›